source
- SimBioSys receives FDA clearance for Nvidia-powered AI tool to predict breast cancer recurrenceSimBioSys announced FDA clearance for its TumorSight Risk platform, an AI-driven tool that uses MRI, pathology and clinical data to assess the likelihood of breast cancer returning. The cloud-base…
- Compass Pathways CEO says company will proceed cautiously as it readies psychedelic therapy for FDA reviewCompass Pathways chief executive Kabir Nath told reporters at the STAT Summit that the company will "go slow before we go fast," emphasizing that early negative experiences could hurt the emerging…